Search Site

Search form

Archived Press Releases

All Releases
View Summary Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis
Nov 18, 2015
PDF 14.3 KB
View Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 10
Nov 4, 2015
PDF 7.4 KB
View Summary Vertex Reports Third Quarter 2015 Financial Results
Oct 28, 2015
PDF 50.4 KB
View Summary Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
Oct 26, 2015
PDF 17.0 KB
View Summary Vertex to Announce Third Quarter 2015 Financial Results on October 28
Oct 9, 2015
PDF 7.6 KB
View Summary Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease
Oct 8, 2015
PDF 30.0 KB
View Summary Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA
Oct 7, 2015
PDF 16.4 KB
View Summary Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union
Sep 25, 2015
PDF 12.1 KB
View Summary Vertex to Present at the Morgan Stanley Healthcare Conference on September 16
Sep 8, 2015
PDF 7.6 KB
View Summary Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts
Aug 19, 2015
PDF 17.7 KB
View Summary Vertex Reports Second Quarter 2015 Financial Results
Jul 29, 2015
PDF 48.1 KB
View Summary Vertex to Announce Second Quarter 2015 Financial Results on July 29
Jul 14, 2015
PDF 7.6 KB
View Summary ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015
PDF 21.5 KB
View Summary FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015
PDF 21.0 KB
View Summary Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
Jun 18, 2015
PDF 8.6 KB
View Summary Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference
Jun 11, 2015
PDF 14.1 KB
View Summary Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015
PDF 16.5 KB
View Summary Vertex to Present at the Goldman Sachs Healthcare Conference on June 11
Jun 3, 2015
PDF 7.6 KB
View Summary New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
May 17, 2015
PDF 12.3 KB
View Summary Vertex to Present at the UBS Healthcare Conference on May 19
May 13, 2015
PDF 6.9 KB
Showing 21-40 of 275 Page: 1 2 3 4 5 6 ... 14  Previous 20 | Next 20